Principal Investigator
Justin Watts
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20251126
Clinical Trial Summary
Phase 1b/2 study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib
Phase
Phase I/II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647